A Note from Our Radiologist
The Tyrer–Cuzick model is the risk tool we use at our practice because it accounts for more variables than most others - including extended family history on both sides and benign breast disease. Understanding your score can be genuinely empowering. It is not a diagnosis. It is a planning tool, and knowing your number puts you in a better position to have an informed conversation with your doctor.
What Is the Tyrer–Cuzick Model?
The Tyrer–Cuzick model - developed by Dr. Jonathan Tyrer and Professor Jack Cuzick at the Wolfson Institute in London - is a validated statistical tool that calculates a woman's estimated lifetime risk of breast cancer. It is also known as the IBIS (International Breast Cancer Intervention Study) model.
Unlike simpler tools that focus on one or two risk factors, the Tyrer–Cuzick model incorporates a large number of personal, hormonal, and family history variables. This makes it one of the most comprehensive and widely validated models available. It is recommended by the American College of Radiology (ACR) and the National Comprehensive Cancer Network (NCCN) for identifying women who may benefit from supplemental screening.
The model produces two key numbers: your 10-year risk (probability of developing breast cancer in the next 10 years) and your lifetime risk (probability of developing breast cancer over your lifetime, typically to age 85). The lifetime risk number is the one most commonly used to guide clinical decisions.
What Information Does the Model Use?
The Tyrer–Cuzick model draws on four broad categories of information. The more complete the data entered, the more accurate the estimate.
Personal History
- Current age
- Age at first period (menarche)
- Age at first live birth
- Number of children
- Menopausal status and age at menopause
- Use of hormone replacement therapy (HRT)
- Body mass index (BMI)
Genetic Factors
- Known BRCA1 or BRCA2 gene mutation status
- Known PALB2, CHEK2, ATM, or other high-risk gene mutations
- Family members with known gene mutations
- Ancestry (e.g., Ashkenazi Jewish heritage increases BRCA prevalence)
Family History
- First-degree relatives with breast cancer (mother, sister, daughter)
- Second-degree relatives with breast cancer (grandmother, aunt)
- Age of each relative at diagnosis
- Whether cancers were bilateral (both breasts)
- Male relatives with breast cancer
- Relatives with ovarian cancer
- Paternal side family history included
Breast Tissue Factors
- Breast density (from mammogram report)
- Prior breast biopsy results
- Atypical ductal hyperplasia (ADH)
- Atypical lobular hyperplasia (ALH)
- Lobular carcinoma in situ (LCIS)
Why family history on both sides matters
Many risk tools only ask about your mother's side. The Tyrer–Cuzick model includes your father's side as well - because BRCA mutations and family history of breast and ovarian cancer on the paternal side carry the same weight. A woman whose paternal aunt had breast cancer at age 40 has elevated risk even if her mother had no breast cancer history.
What Does Your Lifetime Risk Score Mean?
Your lifetime risk score is expressed as a percentage - the estimated probability of developing breast cancer during your lifetime. Here is how risk categories are generally interpreted:
The 20% threshold is a guideline, not a hard rule
In practice, the 20% cutoff is best treated as a strong default trigger, but clinical judgment - accounting for lesion history, density, family history, and patient preference - appropriately informs decisions in borderline cases.
Who Should Have a Formal Risk Assessment?
Major radiology and oncology organizations recommend that all women receive a formal breast cancer risk assessment by age 25 - and sooner if they have concerning factors. A Tyrer–Cuzick assessment is especially important if any of the following apply:
A first-degree relative (mother, sister, daughter) was diagnosed with breast cancer, especially before age 50
A family member has a known BRCA1, BRCA2, PALB2, or other high-risk gene mutation
You are of Ashkenazi Jewish descent, where BRCA mutations occur at higher frequency
You are a Black woman - who face statistically higher rates of aggressive, early-onset breast cancer
You have had a prior breast biopsy showing atypical hyperplasia (ADH, ALH) or lobular carcinoma in situ (LCIS)
You received radiation to your chest between the ages of 10 and 30 (e.g., for Hodgkin's lymphoma)
Your mammogram has shown you have dense breast tissue (Category C or D)
You have multiple relatives on either side of the family with breast, ovarian, or pancreatic cancer
How Does Tyrer–Cuzick Compare to Other Risk Models?
Several validated risk models exist. Each was developed for a slightly different purpose, and they vary in what information they require and how well they perform in different populations.
| Model | Key Inputs | Strengths | Limitations |
|---|---|---|---|
| Tyrer–Cuzick (IBIS) | Personal + detailed family history (both sides), hormonal factors, benign biopsy, density, genetics | Most comprehensive; validated across many populations; includes paternal side; accounts for benign breast disease | Requires more data to complete; can underestimate risk in women with BRCA mutations if mutation testing not performed |
| Gail Model (BCRAT) | Age, race, first period age, first birth age, prior biopsies, first-degree relatives | Simple; widely used; fast to complete | Only includes first-degree relatives; does not account for paternal history, second-degree relatives, or age at relative's diagnosis |
| BRCAPRO | Personal and family history of breast and ovarian cancer; mutation testing results | Strong at estimating BRCA mutation probability | Focuses on genetic mutation probability; less suited for general lifetime risk estimation in average-risk women |
| Claus Model | Family history across two generations | Good for women with significant family history when genetic testing not available | Does not include hormonal or non-genetic risk factors; less used in current clinical practice |
| BOADICEA | Extended family history, genetic mutations, lifestyle factors | Very detailed; accounts for multiple gene mutations beyond BRCA | Complex to administer; typically used in specialist genetics clinics |
Why we use Tyrer–Cuzick at our practice
Among available models, Tyrer–Cuzick best reflects how a radiologist thinks about breast cancer risk: it captures genetic factors, both sides of the family tree, breast tissue characteristics, and reproductive history in a single estimate. It is the model recommended by the ACR for determining MRI eligibility in the screening setting.
What Happens After Your Risk Is Calculated?
A Tyrer–Cuzick score does not stand alone. It is one piece of information that feeds into a broader screening conversation. Here is what typically follows a formal risk assessment:
Your primary care physician, gynecologist, or breast imaging radiologist will review your score and place it in context with your overall health, breast density, and any other relevant findings.
If your lifetime risk is 20% or higher, annual breast MRI will typically be recommended alongside your annual mammogram. The starting age depends on your specific risk profile - often age 25 to 30 for the highest-risk patients.
If your score and family history suggest a meaningful probability of carrying a BRCA or other hereditary mutation, referral to a genetic counselor is often the next step. Formal genetic testing provides certainty that the model alone cannot.
For women in the highest risk categories, physicians may discuss chemoprevention (medications such as tamoxifen or raloxifene that reduce risk) or, in select cases, risk-reducing surgery. These conversations happen with a breast surgeon or oncologist.
Risk is not static. New family history, biopsy results, or changes in breast density can all update your estimated risk. Formal reassessment every few years - or whenever your personal or family history changes significantly - is reasonable.
Limitations of the Model
No risk model is perfect. Understanding what the Tyrer–Cuzick model can and cannot do helps set realistic expectations:
It estimates probability, not destiny
A lifetime risk of 30% means that roughly 3 in 10 women with that profile would develop breast cancer over their lifetime - but it also means 7 in 10 would not. A high score is a reason for vigilant screening, not panic. A low score does not mean cancer is impossible.
Additional limitations to be aware of:
- The model performs best when complete family history data is available. Unknown or incomplete family histories reduce accuracy.
- The model may underestimate risk in women who have not yet had genetic testing but carry an undetected mutation.
- It was developed primarily from European populations. Performance in some racial and ethnic groups - particularly Asian and Hispanic women - may vary.
- Risk estimates are averages across populations. Individual biology, lifestyle, and environmental factors introduce variability that no statistical model can fully capture.
Frequently Asked Questions
Is the Tyrer–Cuzick model the same as the Gail model?
No. The Gail model (now called the Breast Cancer Risk Assessment Tool, or BCRAT) is a different and simpler tool. It uses fewer inputs and only asks about first-degree relatives on the maternal side. The Tyrer–Cuzick model is generally considered more comprehensive and is the model most commonly used in breast imaging practices to determine MRI eligibility.
Can I calculate my own Tyrer–Cuzick score online?
Yes - a version of the IBIS Risk Evaluator is available online at the Wolfson Institute website (ibis-risk-evaluator.magview.com). However, the most accurate results come from a formal assessment performed with your radiologist or physician who can ensure all inputs are entered correctly and can interpret the result in clinical context. Self-calculated scores are useful for initial awareness, not for making clinical decisions independently.
My score came back above 20%. What should I do right now?
The most important step is to bring this result to your primary care physician or gynecologist if they are not already aware of it. Ask specifically whether annual breast MRI in addition to mammography is appropriate for you. If your score is substantially above 20% and you have not had genetic testing, a referral to a genetic counselor is also worth discussing. A score above 20% is actionable - it should change your screening plan - but it is not a reason for alarm.
My mother and sister had breast cancer. Does that automatically make me high risk?
Having two first-degree relatives with breast cancer is a significant risk factor, and it is very likely to push a Tyrer–Cuzick score above the 20% threshold - particularly if those diagnoses occurred before age 50 or involved both breasts. However, the exact impact on your score depends on other variables including the relatives' ages at diagnosis, your own hormonal and reproductive history, and breast density. A formal calculation will give you an actual number to work with.
Does having dense breasts automatically increase my Tyrer–Cuzick score?
In versions 8 and later of the IBIS software, breast density is included as a direct input and does contribute to the risk estimate. Dense breast tissue (categories C and D on your mammogram report) is an independent risk factor for breast cancer in addition to reducing mammogram sensitivity. Even if your Tyrer–Cuzick score falls below 20%, dense breasts may independently support supplemental screening in some situations - your care team can help you think through this.
I don't know much about my family history. How accurate will my score be?
Missing family history data reduces the accuracy of the estimate. In practice, the model can still be run with incomplete information - it will generate a conservative estimate based on what is known. If you have limited family history because of adoption, estrangement, or other circumstances, make sure your provider knows this, as it may influence how the result is interpreted and whether additional genetic testing is recommended.
Related Topics
Have a breast imaging report? A board-certified radiologist with extensive subspecialty experience in breast imaging reviews every explanation before it reaches you.
Get My Report Explained